Metabolic abnormalities and cardiovascular risk in HIV-infected cohort of patients treated with protease inhibitors
Conclusion The study confirms differences in CV risk factors between different cART drugs and this should be considered during initiation of the therapy.
Source: HIV and AIDS Review - Category: Infectious Diseases Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Heart | HIV AIDS | Infectious Diseases | Kaletra | Norvir | Statistics | Study | Women